There was good news today for US biotech giant Gilead Sciences (Nasdaq: GILD), when the US Food and Drug Administration gave its approval for the company’s Epclusa (sofosbuvir/velpatasvir), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Following the announcement, Gilead’s shares rose more than 4% to $81.42 by mid-morning trading. Gilead already has two of the best selling HCV drugs, Harvoni (ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir), which generated combined sales of $4.29 billion in first-quarter 2016. However, one of the biggest problems with Harvoni and Sovaldi is that the drugs are indicated for only certain genotypes of Hepatitis C.
Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin. Epclusa for 12 weeks was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C). Just last month, the European Medicines Agency recommended approval of Epclusa, with a final decision probably expected in August.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze